<DOC>
	<DOCNO>NCT02599168</DOCNO>
	<brief_summary>Dexmedetomidine , selective alpha-2 agonist agent use maintain sedation intensive care patient receipt mechanical ventilation , increasingly utilized anaesthesia practice facilitate anaesthesia depth adjunct base anaesthetic ( intravenous ; propofol : inhalational ; sevoflurane , desflurane ) . The investigator intend assess anaesthetic potential dexmedetomidine control anaesthesia setting empower use objective , patient response base , safe , efficient , patent closed loop anaesthesia delivery system ( CLADS ) . CLADS function control process EEG response parameter capture anaesthetized patient help BIS- monitor , continuously feed automate drug infusion pump . The infusion pump accordingly deliver anaesthetic drug patient base pharmacodynamic requirement . If dexmedetomidine anaesthesia potential likely propofol use deliver CLADS reduce . In addition effect two drug ( viz , base agent-propofol plus adjunct agent-dexmedetomidine ) different receptor site within brain would help gain great anaesthetic depth consistency well low incidence intraoperative patient awareness . This prospective randomize two-arm study aim assess effect use dexmedetomidine propofol requirement ( primary objective ) , anaesthesia depth consistency , intraoperative patient awareness ( secondary objective ) .</brief_summary>
	<brief_title>Effect Dexmedetomidine Propofol Requirement During Anesthesia</brief_title>
	<detailed_description>After Institutional Ethics Committee approval write informed consent , eighty patient-participants ( 40 per group ) age 20-65 year , ASA physical status I/II , either sex , undergo major laparoscopic / robotic surgery 60-minutes duration include single-center ( Sir Ganga Ram Hospital , New Delhi-110060 , India ) prospective , double-blinded , two-arm , randomize control study . The patient randomly divide two group : Group-I : Pre-induction dexmedetomidine + intraoperative dexmedetomidine plus anesthesia propofol deliver CLADS ( induction + maintenance ) [ Dexmedetomidine group ] Group-II : Pre-induction 0.9 % saline solution + intraoperative 0.9 % saline solution infusion + anesthesia propofol deliver CLADS ( induction + maintenance ) [ Non Dexmedetomidine group ] Sample-size Estimation : The sample size estimation estimate cue average propofol dos require maintenance anaesthesia ( 4.7+ 1.6 mg/kg/hr ) use manual propofol remifentanil target control infusion18 90 % power employ detect 30 % decrease propofol dosage among patient receive dexmedetomidine addition base anesthetic propofol ; bilateral α risk value 0.05 , investigator would require 66 patient study . To cover unanticipated loss investigator would need additional 20 % patient . Thus investigator would require 80-patients study Randomization , Allocation Concealment : The patient randomly allocate one two group base computer-generated random number table ( url : stattrek.com/statistics/random-number-generator.aspx ) . Randomization sequence concealment include opaque-sealed envelope alphabetic code whose distribution control independent analyst . The envelope open ; patient 's data-slip paste , send back control analyst . Management Anaesthesia : Two peripheral venous line ( 18G/20G catheter ) secure . Invasive vascular access ( arterial line direct continuous blood pressure assessment , central venous catheter ) secure per requirement surgery and/or patient morbid status . A BIS sensor ( Covidien IIc , Mansfield , USA ) monitoring depth anaesthesia , use BIS monitoring module ( Model DSC-XP , Aspect medical system , USA ) , apply patient 's forehead accord manufacturer 's instruction prior induction anaesthesia . The patient randomly allocate one two group separate method dexmedetomidine administration . The pre-induction infusion dose dexmedetomidine 1-µ/kg 10 minute 0.5-µ/kg/hour , respectively . Dexmedetomidine infusion stop case acute haemodynamic suppression ( &gt; 20 % pre-induction baseline ) acute blood loss ( &gt; 200-ml ) point time record event . It restart upon normalcy haemodynamics achieve also full surgical hemostasis ensure . Anesthesia Technique : All patient administer pre-induction fentanyl-citrate analgesia per predefined strategy ( total 2-µg/kg IV : 1-µg/kg 0 minute , 3-minutes time point ] . Pre-oxygenation initiated 6-minute time point prior fall oxygen saturation &lt; 94 percent . At 9-minute time point anaesthesia induce propofol 2-mg/kg vecuronium bromide 0.08-mg/kg skeletal muscle relaxation facilitate tracheal intubation . Ventilator setting CMV , tracheal tube size [ 7.5-mm I.D ( male ) , 6.5-mm I.D ( female ) ] breathe circuit ( circle-CO2 absorber system ) standardize patient . Routine monitoring ( EKG , NIBP , pulse oximetery , EtCO2 ) apply procedure per establish practice . Over use study drug dexmedetomidine per group allocation , propofol administration control CLADS system tune consistent anaesthetic depth ( BIS 40-60 ) patient . In addition , patient receive 0.5-µg/kg/hr fentanyl infusion surgery . Oxygen.-air mixture ( FiO2 0.50 ) utilized intraoperative ventilation . Neostigmine ( 50-µg/kg ) glycopyrrolate ( 20-µg/kg ) administer reverse residual neuromuscular blockade ( non-depolariser ) .</detailed_description>
	<mesh_term>Anesthetics</mesh_term>
	<mesh_term>Propofol</mesh_term>
	<mesh_term>Dexmedetomidine</mesh_term>
	<criteria>1 . ASA physical status I/II 2 . Undergoing elective laparoscopic / robotic surgery 60minutes duration 1 . Cardiovascular disorder ( uncontrolled hypertension , Atrioventricular block , sinus bradycardia , congenital heart disease , reduce LV compliance &amp; diastolic dysfunction ) 2 . Neurological disorder ( previous neurosurgery , psychiatric disorder , autonomic nervous system disorder orthostatic hypotension , transient ischemic attack ) 3 . Any hepatorenal insufficiency 4 . Uncontrolled diabetes mellitus 5 . Known allergy/hypersensitivity study drug 6 . Pulmonary dysfunction ( restrictive /obstructive lung disease ) 7 . Acute/chronic drug dependence/substance abuse</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>dexmedetomidine</keyword>
	<keyword>propofol</keyword>
	<keyword>BIS</keyword>
	<keyword>CLADS</keyword>
</DOC>